Department of Otorhinolaryngology-Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510630, P.R. China.
Department of Ophthalmology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510630, P.R. China.
Sci Rep. 2017 Aug 10;7(1):7734. doi: 10.1038/s41598-017-07293-7.
Between July 2014 and November 2015, we compared the curative effects and cost-effectiveness of two kinds of nasal endoscopic surgery for nasolacrimal duct obstruction (NLDO) in a single-centre, two-armed clinical trial with a 1-year follow-up. We included two groups: a recessive spherical headed silicone intubation (RSHSI) group and an endonasal dacryocystorhinostomy (En-DCR) group; both received nasal endoscopy. Patients were recruited from the Otorhinolaryngology and Ophthalmology departments. The main outcome measures were epiphora improvement (classified as cure, effective, or invalid), cost-effectiveness, visual analogue scale (VAS) intraoperative pain score, bleeding volume, operating time, hospitalisation time, total cost, and VAS postoperative epiphora score. No significant group difference was identified in postoperative epiphora VAS scores (P > 0.050) or success rate (P = 0.406). However, average VAS intraoperative pain score, operating time, bleeding volume, hospitalisation time and total cost in the RSHSI group were clearly lower to those in the En-DCR group (P = 0.000). In conclusion, RSHSI under nasal endoscopy can provide similar treatment outcomes to En-DCR. RSHSI has advantages including minimal invasiveness, reduced risk, shorter duration of surgery and hospitalisation, reduced intraoperative discomfort, and lower financial burden, which is more acceptable to patients. Thus, RSHSI may be the preferred option for NLDO.
在 2014 年 7 月至 2015 年 11 月期间,我们在一个单中心、双臂临床试验中比较了两种鼻内窥镜手术治疗鼻泪管阻塞(NLDO)的疗效和成本效益,随访时间为 1 年。我们纳入了两组:隐性球形硅胶管(RSHSI)组和经鼻内窥镜泪囊鼻腔吻合术(En-DCR)组;两组均接受鼻内窥镜检查。患者从耳鼻喉科和眼科招募。主要观察指标为溢泪改善(分为治愈、有效和无效)、成本效益、视觉模拟量表(VAS)术中疼痛评分、出血量、手术时间、住院时间、总费用和 VAS 术后溢泪评分。术后溢泪 VAS 评分(P>0.050)或成功率(P=0.406)无明显组间差异。然而,RSHSI 组的平均 VAS 术中疼痛评分、手术时间、出血量、住院时间和总费用明显低于 En-DCR 组(P=0.000)。总之,鼻内窥镜下 RSHSI 可提供与 En-DCR 相似的治疗效果。RSHSI 具有微创、风险低、手术和住院时间短、术中不适减轻、经济负担低等优点,更受患者接受。因此,RSHSI 可能是 NLDO 的首选治疗方法。